Surface Analytical Techniques in Solid-State Particle Characterization for Predicting Performance in Dry Powder Inhalers
Source abstract
Abstract
The pulmonary route is of interest for both effective local therapy for respiratory and lung diseases, such as asthma, chronic obstructive pulmonary disease and cystic fibrosis, and systemic administration of drugs, such as proteins and peptides. Dry powder inhalers (DPIs) are devices through which a dry powder formulation of drug is delivered via the pulmonary route. The DPIs are highly efficient but complicated systems, the performance of which relies on many aspects, including aerodynamic diameter of the powder formulation, particle density, bulk density, surface morphology and composition, particle shape, interparticulate cohesive forces between drug particles and interparticulate adhesive forces between drug and carrier particles. Among them, surface morphology of both drug particles and carrier particles within the formulation is a very important factor in determining the interparticulate contact area and forces, aerosolization efficiency and subsequent lung deposition. Techniques that have been applied to study surface properties of solid-state particles in DPIs include atomic force microscopy, micro- and nano-thermal analysis, inverse gas chromatography and X-ray photoelectron spectroscopy. This paper reviews different aspects of DPIs, with emphasis on their surface properties and influence on aerosol performance, and the techniques that are utilized to examine their surface properties.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Adsorption, diffusion, and thermodynamic properties of materials · Microencapsulation and Drying Processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences-Drug Development Division
References (100+)
Show source-provided references
1. 1) York, P. (1983): Solid-state Properties of Powders in the Formulation and Processing of Solid Dosage Forms, Int. J. Pharm., 14. pp.1–28.10.1016/0378-5173(83)90111-4 ↗
2. 2) Cui, Y. (2007): A Material Science Perspective of Pharmaceutical Solids, Int. J. Pharm., 339. pp.3–18.10.1016/j.ijpharm.2007.04.021 ↗
3. 3) Clas, S.D. (2003): The Importance of Characterizing the Crystal Form of the Drug Substance during Drug Development, Curr. Opin. Drug Discov. Devel., 6. pp.550–560.
4. 4) Datta, S. and Grant, D.J. (2004): Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering, Nat. Rev. Drug Discov., 3. pp.42–57.10.1038/nrd1280 ↗
5. 5) Vippagunta, S.R., Brittain, H.G. and Grant, D.J. (2001): Crystalline Solids, Adv. Drug Deliv. Rev., 48. pp.3–26.10.1016/S0169-409X(01)00097-7 ↗
6. 6) Hancock, B.C. and Zografi, G. (1997): Characteristics and Significance of the Amorphous State in Pharmaceutical Systems, J. Pharm. Sci., 86. pp.1–12.10.1021/js9601896 ↗
7. 7) Hilden, L.R. and Morris, K.R. (2004): Physics of Amorphous Solids, J. Pharm. Sci., 93. pp.3–12.10.1002/jps.10489 ↗
8. 8) Kaushal, A.M., Gupta, P. and Bansal, A.K. (2004): Amorphous Drug Delivery Systems: Molecular Aspects, Design, and Performance, Crit. Rev. Ther. Drug Carrier Syst., 21. pp.133–193.10.1615/CritRevTherDrugCarrierSyst.v21.i3.10 ↗
9. 9) Yu, L. (2001): Amorphous Pharmaceutical Solids: Preparation, Characterization and Stabilization, Adv. Drug Deliv. Rev., 48. pp.27–42.10.1016/S0169-409X(01)00098-9 ↗
10. 10) Rodriguez-Spong, B., Price, C.P., Jayasankar, A., Matzger, A.J. and Rodriguez-Hornedo, N. (2004): General Principles of Pharmaceutical Solid Polymorphism: A Supramolecular Perspective, Adv. Drug Deliv. Rev., 56. pp.241–274.10.1016/j.addr.2003.10.005 ↗
11. 11) Singhal, D. and Curatolo, W. (2004): Drug Polymorphism and Dosage Form Design: A Practical Perspective, Adv. Drug Deliv. Rev., 56. pp.335–347.10.1016/j.addr.2003.10.008 ↗
12. 12) Giron, D., Goldbronn, C., Mutz, M., Pfeffer, S., Piechon, P. and Schwab, P. (2002): Solid State Characterizations of Pharmaceutical Hydrates, J. Therm. Anal. Calorim., 68. pp.453–465.10.1023/A:1016031517430 ↗
13. 13) Bouche, R. and Draguet-Brughmans, M. (1977): Polymorphism of Organic Drug Substances, J. Pharm. Belg., 32. pp.23–51.
14. 14) Li, H., Kiang, Y.H. and Jona, J. (2009): Multiple Approaches to Pharmaceutical Polymorphism Investigation–A Case Study, Eur. J. Pharm. Sci., 38. pp.426–432.10.1016/j.ejps.2009.09.003 ↗
15. 15) Byrn, S.R. (1982): “Solid State Chemistry of Drugs”, Academic Press, New York.
16. 16) Hilfiker, R. (2006): “Polymorphism in the Pharmaceutical Industry”, Wiley-VCH, Weinheim.10.1002/3527607889 ↗
17. 17) Haleblian, J. and McCrone, W. (1969): Pharmaceutical Applications of Polymorphism, J. Pharm. Sci., 58. pp.911–929.10.1002/jps.2600580802 ↗
18. 18) Ghebremeskel, A.N., Vemavarapu, C. and Lodaya, M. (2007): Use of Surfactants as Plasticizers in Preparing Solid Dispersions of Poorly Soluble API: Selection of Polymer-surfactant Combinations Using Solubility Parameters and Testing the Processability, Int. J. Pharm., 328. pp.119–129.10.1016/j.ijpharm.2006.08.010 ↗
19. 19) Genina, N., Raikkonen, H., Ehlers, H., Heinamaki, J., Veski, P. and Yliruusi, J. (2010): Thin-coating as an Alternative Approach to Improve Flow Properties of Ibuprofen Powder, Int. J. Pharm., 387. pp.65–70.10.1016/j.ijpharm.2009.12.005 ↗
20. 20) Lee, Y.S., Poynter, R., Podczeck, F. and Newton, J.M. (2000): Development of a Dual Approach to Assess Powder Flow from Avalanching Behavior, AAPS Pharm Sci. Tech., 1, Article 21.10.1208/pt010321 ↗
21. 21) Builders, P.F., Ibekwe, N., Okpako, L.C., Attama, A.A. and Kunle, O.O. (2009): Preparation and Characterization of Mucinated Cellulose Microparticles for Therapeutic and Drug Delivery Purposes, Eur. J. Pharm. Biopharm., 72. pp.34–41.10.1016/j.ejpb.2008.12.011 ↗
22. 22) Taylor, M.K., Ginsburg, J., Hickey, A. and Gheyas, F. (2000): Composite Method to Quantify Powder Flow as a Screening Method in Early Tablet or Capsule Formulation Development, AAPS Pharm Sci. Tech., 1, Article 18.10.1208/pt010318 ↗
23. 23) Hickey, A.J., Jackson, G.V. and Fildes, F.J. (1988): Preparation and Characterization of Disodium Fluorescein Powders in Association with Lauric and Capric Acids, J. Pharm. Sci., 77. pp.804–809.10.1002/jps.2600770919 ↗
24. 24) Taylor, L.S. and Zografi, G. (1998): The Quantitative Analysis of Crystallinity Using FT-Raman Spectroscopy, Pharm. Res., 15. pp.755–761.10.1023/A:1011979221685 ↗
25. 25) Newman, A.W. and Byrn, S.R. (2003): Solid-state Analysis of the Active Pharmaceutical Ingredient in Drug Products, Drug Discov. Today, 8. pp.898–905.10.1016/S1359-6446(03)02832-0 ↗
26. 26) Hickey, A.J., Mansour, H.M., Telko, M.J., Xu, Z., Smyth, H.D., Mulder, T., McLean, R., Langridge, J. and Papadopoulos, D. (2007): Physical Characterization of Component Particles Included in Dry Powder Inhalers. I. Strategy Review and Static Characteristics, J. Pharm. Sci., 96. pp.1282–1301.10.1002/jps.20916 ↗
27. 27) Strom, C.S. (1975): Indexing of Crystal Faces on Sem Photographs, Acta Crystallographica Section A, 31. pp.S216–S216.
28. 28) Rebanta Bandyopadhyay and David J. W. Grant (2000): Influence of Crystal Habit on the Surface Free Energy and Interparticulate Bonding of L-Lysine Monohydrochloride Dihydrate, Pharm. Dev. Technol., 5. pp.27–37.10.1081/PDT-100100516 ↗
29. 29) Muster, T.H. and Prestidge, C.A. (2002): Face Specific Surface Properties of Pharmaceutical Crystals, J. Pharm. Sci., 91. pp.1432–1444.10.1002/jps.10125 ↗
30. 30) Hancock, B.C. and Parks, M. (2000): What Is the True Solubility Advantage for Amorphous Pharmaceuticals?, Pharm. Res., 17. pp.397–404.10.1023/A:1007516718048 ↗
31. 31) Dannenfelser, R.M., He, H., Joshi, Y., Bateman, S. and Serajuddin, A.T. (2004): Development of Clinical Dosage Forms for a Poorly Water Soluble Drug I: Application of Polyethylene Glycol-polysorbate 80 Solid Dispersion Carrier System, J. Pharm. Sci., 93. pp.1165–1175.10.1002/jps.20044 ↗
32. 32) Craig, D.Q., Royall, P.G., Kett, V.L. and Hopton, M.L. (1999): The Relevance of the Amorphous State to Pharmaceutical Dosage Forms: Glassy Drugs and Freeze Dried Systems, Int. J. Pharm., 179. pp.179–207.10.1016/S0378-5173(98)00338-X ↗
33. 33) Gupta, M.K., Vanwert, A. and Bogner, R.H. (2003): Formation of Physically Stable Amorphous Drugs by Milling with Neusilin, J. Pharm. Sci., 92. pp.536–551.10.1002/jps.10308 ↗
34. 34) Sharma, P., Denny, W.A. and Garg, S. (2009): Effect of Wet Milling Process on the Solid State of Indomethacin and Simvastatin, Int. J. Pharm., 380. pp.40–48.10.1016/j.ijpharm.2009.06.029 ↗
35. 35) Willart, J.F. and Descamps, M. (2008): Solid State Amorphization of Pharmaceuticals, Mol. Pharm., 5. pp.905–920.10.1021/mp800092t ↗
36. 36) Patterson, J.E., James, M.B., Forster, A.H., Lancaster, R.W., Butler, J.M. and Rades, T. (2005): The Influence of Thermal and Mechanical Preparative Techniques on the Amorphous State of Four Poorly Soluble Compounds, J. Pharm. Sci., 94. pp.1998–2012.10.1002/jps.20424 ↗
37. 37) Gupta, P. and Bansal, A.K. (2005): Spray Drying for Generation of a Ternary Amorphous System of Celecoxib, PVP, and Meglumine, Pharm. Dev. Technol., 10. pp.273–281.10.1081/PDT-54460 ↗
38. 38) Healy, A.M., McDonald, B.F., Tajber, L. and Corrigan, O.I. (2008): Characterisation of Excipient-free Nanoporous Microparticles (NPMPs) of Bendroflumethiazide, Eur. J. Pharm. Biopharm., 69. pp.1182–1186.10.1016/j.ejpb.2008.04.020 ↗
39. 39) Horvat, M., Mestrovic, E., Danilovski, A. and Craig, D.Q. (2005): An Investigation into the Thermal Behaviour of a Model Drug Mixture with Amorphous Trehalose, Int. J. Pharm., 294. pp.1–10.10.1016/j.ijpharm.2004.08.025 ↗
40. 40) Kim, J.S., Kim, M.S., Park, H.J., Jin, S.J., Lee, S. and Hwang, S.J. (2008): Physicochemical Properties and Oral Bioavailability of Amorphous Atorvastatin Hemi-calcium Using Spray-drying and SAS Process, Int. J. Pharm., 359. pp.211–219.10.1016/j.ijpharm.2008.04.006 ↗
41. 41) Learoyd, T.P., Burrows, J.L., French, E. and Seville, P.C. (2008): Chitosan-based Spray-dried Respirable Powders for Sustained Delivery of Terbutaline Sulfate, Eur. J. Pharm. Biopharm., 68. pp.224–234.10.1016/j.ejpb.2007.04.017 ↗
42. 42) Takeuchi, H., Nagira, S., Yamamoto, H. and Kawashima, Y. (2005): Solid Dispersion Particles of Amorphous Indomethacin with Fine Porous Silica Particles by Using Spray-drying Method, Int. J. Pharm., 293. pp.155–164.10.1016/j.ijpharm.2004.12.019 ↗
43. 43) Bhattacharya, S. and Suryanarayanan, R. (2009): Local Mobility in Amorphous Pharmaceuticals–Characterization and Implications on Stability, J. Pharm. Sci., 98. pp.2935–2953.10.1002/jps.21728 ↗
44. 44) Liu, J. (2006): Physical Characterization of Pharmaceutical Formulations in Frozen and Freeze-dried Solid States: Techniques and Applications in Freeze-drying Development, Pharm. Dev. Technol., 11. pp.3–28.10.1080/10837450500463729 ↗
45. 45) Xiang, T.X. and Anderson, B.D. (2004): A Molecular Dynamics Simulation of Reactant Mobility in an Amorphous Formulation of a Peptide in Poly(vinylpyrrolidone), J. Pharm. Sci., 93. pp.855–876.10.1002/jps.20004 ↗
46. 46) Bonacucina, G., Palmieri, G.F. and Craig, D.Q. (2005): Rheological and Dielectric Characterization of Monoolein/water Mesophases in the Presence of a Peptide Drug, J. Pharm. Sci., 94. pp.2452–2462.10.1002/jps.20446 ↗
47. 47) Efrat, R., Shalev, D.E., Hoffman, R.E., Aserin, A. and Garti, N. (2008): Effect of Sodium Diclofenac Loads on Mesophase Components and Structure, Langmuir, 24. pp.7590–7595.10.1021/la800603f ↗
48. 48) Stevenson, C.L., Bennett, D.B. and Lechuga-Ballesteros, D. (2005): Pharmaceutical Liquid Crystals: The Relevance of Partially Ordered Systems, J. Pharm. Sci., 94. pp.1861–1880.10.1002/jps.20435 ↗
49. 49) Descamps, M., Correia, N.T., Derollez, P., Danede, F. and Capet, F. (2005): Plastic and Glassy Crystal States of Caffeine, J. Phys. Chem. B, 109. pp.16092–16098.10.1021/jp040494c ↗
50. 50) Rey, R. (2008): Orientational Order and Rotational Relaxation in the Plastic Crystal Phase of Tetrahedral Molecules, J. Phys. Chem. B, 112. pp.344–357.10.1021/jp0754177 ↗
51. 51) Singh, L.P. and Murthy, S.S. (2009): Dielectric and Calorimetric Investigation of an Unusual Two-component Plastic Crystal: Cyclohexanol-neopentylglycol, Phys. Chem. Chem. Phys., 11. pp.5110–5118.10.1039/b817964f ↗
52. 52) Grebowicz, J., Cheng, S.Z.D. and Wunderlich, B. (1986): Kinetics of Transitions Involving Condis Crystals, J. POLYM. SCI. POL. PHYS., 24. pp.675–685.10.1002/polb.1986.090240313 ↗
53. 53) Heinz, A., Strachan, C.J., Gordon, K.C. and Rades, T. (2009): Analysis of Solid-state Transformations of Pharmaceutical Compounds Using Vibrational Spectroscopy, J. Pharm. Pharmacol., 61. pp.971–988.10.1211/jpp/61.08.0001 ↗
54. 54) Bell, J.H., Hartley, P.S. and Cox, J.S. (1971): Dry Powder Aerosols. I. A New Powder Inhalation Device, J. Pharm. Sci., 60. pp.1559–1564.10.1002/jps.2600601028 ↗
55. 55) Telko, M.J. and Hickey, A.J. (2005): Dry Powder Inhaler Formulation, Respir. Care, 50, pp.1209–1227.10.4187/respcare.05501209 ↗
56. 56) Andya, J.D., Maa, Y.F., Costantino, H.R., Nguyen, P.A., Dasovich, N., Sweeney, T.D., Hsu, C.C. and Shire, S.J. (1999): The Effect of Formulation Excipients on Protein Stability and Aerosol Performance of Spray-dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody, Pharm. Res., 16. pp.350–358.10.1023/A:1018805232453 ↗
57. 57) Clarke, M.J., Tobyn, M.J. and Staniforth, J.N. (2000): Physicochemical Factors Governing the Performance of Nedocromil Sodium as a Dry Powder Aerosol, J. Pharm. Sci., 89. pp.1160–1169.10.1002/1520-6017(200009)89:9<1160::AID-JPS8>3.3.CO;2-4 ↗
58. 58) Costantino, H.R., Andya, J.D., Nguyen, P.A., Dasovich, N., Sweeney, T.D., Shire, S.J., Hsu, C.C. and Maa, Y.F. (1998): Effect of Mannitol Crystallization on the Stability and Aerosol Performance of a Spray-dried Pharmaceutical Protein, Recombinant Humanized Anti-IgE Monoclonal Antibody, J. Pharm. Sci., 87. pp.1406–1411.10.1021/js9800679 ↗
59. 59) Junghanns, J.U. and Muller, R.H. (2008): Nanocrystal Technology, Drug Delivery and Clinical Applications, Int. J. Nanomedicine, 3, pp.295–309.10.2147/IJN.S595 ↗
60. 60) Merisko-Liversidge, E., Liversidge, G.G. and Cooper, E.R. (2003): Nanosizing: A Formulation Approach for Poorly-water-soluble Compounds, Eur. J. Pharm. Sci., 18. pp.113–120.10.1016/S0928-0987(02)00251-8 ↗
61. 61) Merisko-Liversidge, E., Sarpotdar, P., Bruno, J., Hajj, S., Wei, L., Peltier, N., Rake, J., Shaw, J.M., Pugh, S., Polin, L., Jones, J., Corbett, T., Cooper, E. and Liversidge, G.G. (1996): Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs, Pharm. Res., 13. pp.272–278.10.1023/A:1016051316815 ↗
62. 62) Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J. and Hickey, A.J. (2010): Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. albuterol sulfate and disodium cromoglycate, J. Pharm. Sci., 99. pp.3398–3414.10.1002/jps.22107 ↗
63. 63) Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J. and Hickey, A.J. (2010): Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate, J. Pharm. Sci., 99. pp.3415–3429.10.1002/jps.22100 ↗
64. 64) Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J. and Hickey, A.J. (2010): Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance, J. Pharm. Sci., 99. pp.3442–3461.10.1002/jps.22057 ↗
65. 65) Mansour, H.M., Xu, Z. and Hickey, A.J. (2010): Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Treha-lose dihydrate and D-mannitol carriers, J. Pharm. Sci., 99. pp.3430–3441.10.1002/jps.22101 ↗
66. 66) Atkins, P.J. (2005): Dry Powder Inhalers: an Overview, Respir. Care, 50. pp.1304–1312; discussion 1312.10.4187/respcare.05501304 ↗
67. 67) Hickey, A.J. and Mansour, H.M., Chapter 5: Delivery of Drugs by the Pulmonary Route, in Modern Pharmaceutics, A.T. Florence and J. Siepmann, Editors. 2009, Taylor and Francis, Inc: New York. pp.191–219.
68. 68) Geller, D.E. (2005): Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler, Respir Care, 50. pp.1313–1321; discussion 1321–2.10.4187/respcare.05501313 ↗
69. 69) Kleinstreuer, C., Zhang, Z. and Donohue, J.F. (2008): Targeted Drug-Aerosol Delivery in the Human Respiratory System, Annu. Rev. Biomed. Eng., 10. pp.195–220.10.1146/annurev.bioeng.10.061807.160544 ↗
70. 70) Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J. and Hickey, A.J., Comparative Dispersion Study of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes, in Respiratory Drug Delivery XI, R.N. Dalby, et al., Editors. 2008, Davis Healthcare International Publishing, LLC: Scotsdale, Arizona. pp.897–900.
71. 71) Young, P.M., Kwok, P., Adi, H., Chan, H.K. and Traini, D. (2009): Lactose composite carriers for respiratory delivery, Pharm Res, 26. pp.802–810.10.1007/s11095-008-9779-9 ↗
72. 72) Hickey, A.J., Mansour, H.M., Telko, M.J., Xu, Z., Smyth, H.D.C., Mulder, T., McLean, R., Langridge, J. and Papadopoulous, D. (2007): Physical Characterization of Component Particles included in Dry Powder Inhalers: II. Dynamic Characteristics, J Pharm Sci, 96. pp.1302–1319.10.1002/jps.20943 ↗
73. 73) Hickey, A.J. and Mansour, H.M., Chapter 43: Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols., in Modified-Release Drug Delivery Technology, M.J. Rathbone, et al., Editors. 2008, Informa Healthcare: New York. pp.573–602.10.3109/9781420045260-44 ↗
74. 74) Montreal protocol (1987): The Montreal protocol on substances that deplete the ozone layers, Ozone Secretariat, United Nations Environment Programme.
75. 75) Newman, S.P. and Clarke, S.W. (1993): Bronchodilator Delivery from Gentlehaler, a New Low-Velocity Pressurized Aerosol Inhaler, Chest, 103. pp.1442–1446.10.1378/chest.103.5.1442 ↗
76. 76) Ganderton, D. (1997): General Factors Influencing Drug Delivery to the Lung, Respir. Med., 91 Suppl A. pp.13–16.10.1016/S0954-6111(97)90099-8 ↗
77. 77) Newman, S.P. and Newhouse, M.T. (1996): Effect of Add-on Devices for Aerosol Drug Delivery: Deposition Studies and Clinical Aspects, J. Aerosol Med., 9. pp.55–70.10.1089/jam.1996.9.55 ↗
78. 78) Borgstrom, L., Derom, E., Stahl, E., Wahlin-Boll, E. and Pauwels, R. (1996): The Inhalation Device Influences Lung Deposition and Bronchodilating Effect of Terbutaline, Am. J. Respir. Crit. Care Med., 153. pp.1636–1640.10.1164/ajrccm.153.5.8630614 ↗
79. 79) Telko, M.J. and Hickey, A.J. (2005): Dry Powder Inhaler Formulation, Respir. Care, 50. pp.1209–1227.10.4187/respcare.05501209 ↗
80. 80) Ashurst, I.I., Malton, A., Prime, D. and Sumby, B. (2000): Latest Advances in the Development of Dry Powder Inhalers, Pharm. Sci. Technolo. Today, 3. pp.246–256.10.1016/S1461-5347(00)00275-3 ↗
81. 81) Norwood, D.L., Prime, D., Downey, B.P., Creasey, J., Sethi, S.K. and Haywood, P. (1995): Analysis of Polycyclic Aromatic Hydrocarbons in Metered Dose Inhaler Drug Formulations by Isotope Dilution Gas Chromatography/Mass Spectrometry, J. Pharm. Biomed. Anal., 13. pp.293–304.10.1016/0731-7085(95)01273-N ↗
82. 82) Howarth, P.H. (1997): What is the Nature of Asthma and Where are the Therapeutic Targets?, Respir. Med., 91 Suppl A. pp.2–8.10.1016/S0954-6111(97)90096-2 ↗
83. 83) Carstairs, J.R., Nimmo, A.J. and Barnes, P.J. (1985): Autoradiographic Visualization of Beta-Adrenoceptor Subtypes in Human Lung, Am. Rev. Respir. Dis., 132. pp.541–547.
84. 84) Barnes, P.J., Basbaum, C.B., Nadel, J.A. and Roberts, J.M. (1982): Localization of Beta-Adrenoreceptors in Mammalian Lung by Light Microscopic Autoradiography, Nature, 299. pp.444–447.10.1038/299444a0 ↗
85. 85) Labiris, N.R. and Dolovich, M.B. (2003): Pulmonary Drug Delivery. Part I: Physiological Factors Affecting Therapeutic Effectiveness of Aerosolized Medications, Br. J. Clin. Pharmacol., 56. pp.588–599.10.1046/j.1365-2125.2003.01892.x ↗
86. 86) Pedersen, S. and O’Byrne, P. (1997): A Comparison of the Efficacy and Safety of Inhaled Corticosteroids in Asthma, Allergy, 52. pp.1–34.10.1111/j.1398-9995.1997.tb02538.x ↗
87. 87) Leach, C.L., Davidson, P.J. and Boudreau, R.J. (1998): Improved Airway Targeting with the CFC-Free HFA-Beclomethasone Metered-Dose Inhaler Compared with CFC-Beclomethasone, Eur. Respir. J., 12. pp.1346–1353.10.1183/09031936.98.12061346 ↗
88. 88) Barnes, P.J., Basbaum, C.B. and Nadel, J.A. (1983): Autoradiographic Localization of Autonomic Receptors in Airway Smooth Muscle. Marked Differences between Large and Small Airways, Am. Rev. Respir. Dis., 127. pp.758–762.
89. 89) Irngartinger, M., Camuglia, V., Damm, M., Goede, J. and Frijlink, H.W. (2004): Pulmonary Delivery of Therapeutic Peptides via Dry Powder Inhalation: Effects of Micronisation and Manufacturing, Eur. J. Pharm. Biopharm., 58. pp.7–14.10.1016/j.ejpb.2004.03.016 ↗
90. 90) Steckel, H., Markefka, P., teWierik, H. and Kammelar, R. (2006): Effect of Milling and Sieving on Functionality of Dry Powder Inhalation Products, Int. J. Pharm., 309. pp.51–59.10.1016/j.ijpharm.2005.10.043 ↗
91. 91) Rasenack, N. and Muller, B.W. (2004): Micron-Size Drug Particles: Common and Novel Micronization Techniques, Pharm. Dev. Technol., 9. pp.1–13.10.1081/PDT-120027417 ↗
92. 92) Dunbar, C.H.A., Hickey, A.J. and Holzner, P. (1998): Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols, KONA Powder and Particle Journal, 16. pp.7–45.10.14356/kona.1998007 ↗
93. 93) Mosen, K., Backstrom, K., Thalberg, K., Schaefer, T., Kristensen, H.G. and Axelsson, A. (2004): Particle Formation and Capture during Spray Drying of Inhalable Particles, Pharm. Dev. Technol., 9. pp.409–417.10.1081/PDT-200035795 ↗
94. 94) Seville, P.C., Li, H.Y. and Learoyd, T.P. (2007): Spray-Dried Powders for Pulmonary Drug Delivery, Crit. Rev. Ther. Drug Carrier Syst., 24. pp.307–360.10.1615/CritRevTherDrugCarrierSyst.v24.i4.10 ↗
95. 95) Weers, J.G., Tarara, T.E. and Clark, A.R. (2007): Design of Fine Particles for Pulmonary Drug Delivery, Expert Opin. Drug Deliv., 4. pp.297–313.10.1517/17425247.4.3.297 ↗
96. 96) Tom, J.W. and Debenedetti, P.G. (1991): Particle formation with supercritical fluids--a review, J Aerosol Sci, 22. pp.555–584.10.1016/0021-8502(91)90013-8 ↗
97. 97) Chow, A.H., Tong, H.H., Chattopadhyay, P. and Shekunov, B.Y. (2007): Particle Engineering for Pulmonary Drug Delivery, Pharm. Res., 24. pp.411–437.10.1007/s11095-006-9174-3 ↗
98. 98) Mansour, H.M., Rhee, Y.S. and Wu, X. (2009): Nano-medicine in Pulmonary Delivery, Int. J. Nanomedicine, 4. pp.299–319.10.2147/IJN.S4937 ↗
99. 99) Ozeki, T., Beppu, S., Mizoe, T., Takashima, Y., Yuasa, H. and Okada, H. (2006): Preparation of Polymeric Submicron Particle-Containing Microparticles Using a 4-Fluid Nozzle Spray Drier, Pharm. Res., 23. pp.177–183.10.1007/s11095-005-8718-2 ↗
100. 100) Elversson, J. and Millqvist-Fureby, A. (2005): Particle Size and Density in Spray Drying-Effects of Carbohydrate Properties, J. Pharm. Sci., 94. pp.2049–2060.10.1002/jps.20418 ↗